Early prediction of fluoxetine response for han chinese inpatients with major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 31, Issue 2, 2011, Pages 187-193

  Lin, Ching Hua ^a,b   Lane, Hsien Yuan ^c,d   Chen, Cheng Chung ^a   Juo, Suh Hang Hank ^e,f,g   Yen, Cheng Fang ^e,f  

^a KAI SUAN PSYCHIATRIC HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c Institute of Clinical Medical Science   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f University College of Medicine   (Taiwan)

^g Center of Excellence for Environmental Medicine   (Taiwan)

Author keywords

early prediction model; fluoxetine; major depressive disorder

Indexed keywords

FLUOXETINE;

ACCOMMODATION DISORDER; ADULT; ARTICLE; ASTHENIA; CHINESE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG RESPONSE; FATIGUE; FEMALE; HAMILTON SCALE; HEART PALPITATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEMORY DISORDER; MENTAL CONCENTRATION; ORTHOSTATIC INTOLERANCE; POLYURIA; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SALIVATION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SLEEP DISORDER;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952453407     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318210856f     Document Type: Article

References (45)

1. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405-418. (Pubitemid 24020594)
2. Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. J Affect Disord. 2002;72:227-236. (Pubitemid 35351282)
3. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(suppl 4):1-45.
4. Katz MM, Koslow SH, Maas JW, et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med. 1987;17:297-309. (Pubitemid 17091389)
5. Derivan AT. Antidepressants: can we determine how quickly they work? Issues from the literature. Psychopharmacol Bull. 1995;31:23-28.
6. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22:343-396. (Pubitemid 351989984)
7. Montgomery SA. Fast-onset antidepressants. Int Clin Psychopharmacol. 1997;12(suppl 3):1-5.
8. Quitkin FM, Rabkin JG, Ross D, et al. Duration of antidepressant drug treatment. What is an adequate trial? Arch Gen Psychiatry. 1984;41:238-245. (Pubitemid 14168077)
9. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009;195:102-108.
10. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry. 1996;53:785-792. (Pubitemid 26303619)
11. Donovan SJ, Quitkin FM, Stewart JW, et al. Duration of antidepressant trials: clinical and research implications. J Clin Psychopharmacol. 1994;14:64-66. (Pubitemid 24076182)
12. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000;157:1423-1428.
13. Wernicke JF, Dunlop SR, Dornseif BE, et al. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1987;23:164-168. (Pubitemid 17111687)
14. Frazer A, Benmansour S. Delayed pharmacological effects of antidepressants. Mol Psychiatry. 2002;7(suppl 1):23-28.
15. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917. (Pubitemid 44807782)
16. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol. 1987;7(suppl 6):24-35.
17. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597-606. (Pubitemid 27306570)
18. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry. 1996;153:151-162. (Pubitemid 26038955)
19. Guidelines on psychotropic drugs for the EC. Committee for Proprietary Medicinal Products. European Economic Community. Eur Neuropsychopharmacol. 1994;4:61-77.
20. Reesal RT, Lam RW. Clinical guidelines for the treatment of depressive disorders. II. Principles of management. Can J Psychiatry. 2001;46(suppl):1:21- 28.
21. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007;8:67-104. (Pubitemid 46690921)
22. Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149:725-733.
23. Sackeim HA, Roose SP, Lavori PW. Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD). Biol Psychiatry. 2006;59:483-492. (Pubitemid 43320535)
24. Katz MM, Tekell JL, Bowden CL, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004;29:566-579. (Pubitemid 38365934)
25. Papakostas GI, Perlis RH, Scalia MJ, et al. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006;26:56-60. (Pubitemid 43167092)
26. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry. 2005;66:148-158. (Pubitemid 40314320)
27. Stassen HH, Angst J, Hell D, et al. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry. 2007;68:1195-1205. (Pubitemid 47395621)
28. Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70:344-353.
29. Taylor MJ, Freemantle N, Geddes JR, et al. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry. 2006;63:1217-1223. (Pubitemid 44708080)
30. Szegedi A, Muller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64:413-420. (Pubitemid 36547285)
31. Quitkin FM, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003;160:734-740. (Pubitemid 41079607)
32. Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007;68:352-360. (Pubitemid 46506798)
33. American Psychiatric Association. Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiatric Press; 1994.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
35. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: DHEW Publication; 1976:76338.
36. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100. (Pubitemid 17115352)
37. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
38. Davidson JR, Meoni P, Haudiquet V, et al. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16:4-13. (Pubitemid 34977120)
39. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869-877. (Pubitemid 33131173)
40. Schweizer E, Rickels K, Amsterdam JD, et al. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry. 1990;51:8-11. (Pubitemid 20042560)
41. Stokes PE. Fluoxetine: a five-year review. Clin Ther. 1993;15:216-243. (Pubitemid 23168487)
42. Beasley CM Jr, Nilsson ME, Koke SC, et al. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. J Clin Psychiatry. 2000;61:722-728.
43. Gram L. Fluoxetine. N Engl J Med. 1994;331:1354-1361. (Pubitemid 24984727)
44. Khan A, Leventhal RM, Khan SR, et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22:40-45. (Pubitemid 34101291)
45. Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995;152:1500-1503.